DNABW (Ginkgo Bioworks Holdings) Research & Development: $222.77 Mil (TTM As of Mar. 2026)


DNABW Ginkgo Bioworks Holdings Inc DNABW
63 GF Score
Price $0.00
! 5 Warning Signs
View Full Analysis

What is Ginkgo Bioworks Holdings Research & Development?

Ginkgo Bioworks Holdings DNABW -18.18% 63 Research & Development is $222.77 Mil as of Mar. 2026. GuruFocus rates DNABW with a GF Score™ of 63/100. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Ginkgo Bioworks Holdings's Research & Development for the three months ended in Mar. 2026 was $49.92 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $222.77 Mil.

Ginkgo Bioworks Holdings  (OTCPK:DNABW) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Ginkgo Bioworks Holdings Research & Development Related Terms

Ginkgo Bioworks Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Ginkgo Bioworks Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ginkgo Bioworks Holdings Research & Development Chart

Ginkgo Bioworks Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 1,149.66 1,052.64 580.62 424.06 243.77

Ginkgo Bioworks Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 70.92 53.37 69.35 50.13 49.92
DNABW
63GF Score
Ginkgo Bioworks Holdings Inc DNABW
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ginkgo Bioworks Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $222.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $222.77 Mil mean?
Ginkgo Bioworks Holdings (DNABW) has a Research & Development of $222.77 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Ginkgo Bioworks Holdings and its competitors.
Is Ginkgo Bioworks Holdings' Research & Development too high?
Ginkgo Bioworks Holdings' current Research & Development is $222.77 Mil. Overall, Ginkgo Bioworks Holdings has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Ginkgo Bioworks Holdings' Research & Development compare to CADL and CABA?
Ginkgo Bioworks Holdings' Research & Development of $222.77 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Ginkgo Bioworks Holdings and its competitors. Ginkgo Bioworks Holdings's current Research & Development is $222.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ginkgo Bioworks Holdings stock overvalued right now?
Ginkgo Bioworks Holdings (DNABW) has a current Research & Development of $222.77 Mil. The current Research & Development is $222.77 Mil. Ginkgo Bioworks Holdings' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Ginkgo Bioworks Holdings (DNABW), the current Research & Development is $222.77 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ginkgo Bioworks Holdings Business Description

Other Exchanges DNA:USADNA:Mexico
Address 27 Drydock Avenue, 8th Floor, Boston, MA, USA, 02210
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
63GF Score

Get the complete analysis for DNABW

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price